Annual Accounts Payable
$112.20 M
+$8.70 M+8.41%
31 December 2023
Summary:
Emergent BioSolutions annual accounts payable is currently $112.20 million, with the most recent change of +$8.70 million (+8.41%) on 31 December 2023. During the last 3 years, it has fallen by -$23.90 million (-17.56%). EBS annual accounts payable is now -17.56% below its all-time high of $136.10 million, reached on 31 December 2020.EBS Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$82.10 M
-$13.80 M-14.39%
30 September 2024
Summary:
Emergent BioSolutions quarterly accounts payable is currently $82.10 million, with the most recent change of -$13.80 million (-14.39%) on 30 September 2024. Over the past year, it has dropped by -$30.60 million (-27.15%). EBS quarterly accounts payable is now -45.92% below its all-time high of $151.80 million, reached on 30 June 2021.EBS Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EBS Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +8.4% | -27.1% |
| 3 y3 years | -17.6% | -39.3% |
| 5 y5 years | +39.0% | -10.1% |
EBS Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -17.6% | +8.4% | -39.3% | at low |
| 5 y | 5 years | -17.6% | +39.0% | -45.9% | at low |
| alltime | all time | -17.6% | +1932.6% | -45.9% | +1387.3% |
Emergent BioSolutions Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $82.10 M(-14.4%) |
| June 2024 | - | $95.90 M(-4.3%) |
| Mar 2024 | - | $100.20 M(-10.7%) |
| Dec 2023 | $112.20 M(+8.4%) | $112.20 M(-0.4%) |
| Sept 2023 | - | $112.70 M(+4.1%) |
| June 2023 | - | $108.30 M(-12.8%) |
| Mar 2023 | - | $124.20 M(+20.0%) |
| Dec 2022 | $103.50 M(-19.7%) | $103.50 M(-0.3%) |
| Sept 2022 | - | $103.80 M(-2.3%) |
| June 2022 | - | $106.20 M(-1.0%) |
| Mar 2022 | - | $107.30 M(-16.8%) |
| Dec 2021 | $128.90 M(-5.3%) | $128.90 M(-4.7%) |
| Sept 2021 | - | $135.20 M(-10.9%) |
| June 2021 | - | $151.80 M(+6.8%) |
| Mar 2021 | - | $142.20 M(+4.5%) |
| Dec 2020 | $136.10 M(+43.6%) | $136.10 M(+32.4%) |
| Sept 2020 | - | $102.80 M(+21.2%) |
| June 2020 | - | $84.80 M(+0.7%) |
| Mar 2020 | - | $84.20 M(-11.2%) |
| Dec 2019 | $94.80 M(+17.5%) | $94.80 M(+3.8%) |
| Sept 2019 | - | $91.30 M(-26.7%) |
| June 2019 | - | $124.50 M(+58.4%) |
| Mar 2019 | - | $78.60 M(-2.6%) |
| Dec 2018 | $80.70 M(+93.1%) | $80.70 M(+107.6%) |
| Sept 2018 | - | $38.87 M(-6.6%) |
| June 2018 | - | $41.63 M(-9.9%) |
| Mar 2018 | - | $46.22 M(+10.6%) |
| Dec 2017 | $41.80 M(+20.6%) | $41.80 M(+38.8%) |
| Sept 2017 | - | $30.11 M(+1.7%) |
| June 2017 | - | $29.60 M(+8.9%) |
| Mar 2017 | - | $27.18 M(-21.6%) |
| Dec 2016 | $34.65 M(-8.7%) | $34.65 M(-25.2%) |
| Sept 2016 | - | $46.34 M(-21.4%) |
| June 2016 | - | $58.97 M(+29.3%) |
| Mar 2016 | - | $45.61 M(+20.1%) |
| Dec 2015 | $37.97 M | $37.97 M(-7.9%) |
| Sept 2015 | - | $41.25 M(-1.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2015 | - | $41.82 M(+3.1%) |
| Mar 2015 | - | $40.58 M(-0.8%) |
| Dec 2014 | $40.93 M(+48.7%) | $40.93 M(+4.0%) |
| Sept 2014 | - | $39.35 M(+6.4%) |
| June 2014 | - | $36.97 M(+0.9%) |
| Mar 2014 | - | $36.64 M(+33.1%) |
| Dec 2013 | $27.52 M(-12.1%) | $27.52 M(-5.2%) |
| Sept 2013 | - | $29.02 M(+12.9%) |
| June 2013 | - | $25.71 M(+7.7%) |
| Mar 2013 | - | $23.87 M(-23.7%) |
| Dec 2012 | $31.30 M(-22.8%) | $31.30 M(+14.4%) |
| Sept 2012 | - | $27.35 M(+17.4%) |
| June 2012 | - | $23.30 M(-17.7%) |
| Mar 2012 | - | $28.32 M(-30.1%) |
| Dec 2011 | $40.53 M(+59.5%) | $40.53 M(+19.6%) |
| Sept 2011 | - | $33.90 M(+5.3%) |
| June 2011 | - | $32.18 M(+33.9%) |
| Mar 2011 | - | $24.03 M(-5.4%) |
| Dec 2010 | $25.41 M(+48.1%) | $25.41 M(+12.8%) |
| Sept 2010 | - | $22.52 M(+10.9%) |
| June 2010 | - | $20.30 M(+25.6%) |
| Mar 2010 | - | $16.16 M(-5.8%) |
| Dec 2009 | $17.16 M(-6.0%) | $17.16 M(-19.2%) |
| Sept 2009 | - | $21.24 M(+20.9%) |
| June 2009 | - | $17.57 M(+2.2%) |
| Mar 2009 | - | $17.19 M(-5.9%) |
| Dec 2008 | $18.25 M(+1.5%) | $18.25 M(+9.5%) |
| Sept 2008 | - | $16.67 M(-16.4%) |
| June 2008 | - | $19.93 M(+11.6%) |
| Mar 2008 | - | $17.86 M(-0.6%) |
| Dec 2007 | $17.98 M(-34.3%) | $17.98 M(-7.2%) |
| Sept 2007 | - | $19.38 M(+11.7%) |
| June 2007 | - | $17.35 M(-8.7%) |
| Mar 2007 | - | $19.00 M(-30.6%) |
| Dec 2006 | $27.37 M(+162.5%) | $27.37 M(+65.1%) |
| Sept 2006 | - | $16.57 M(+59.0%) |
| Dec 2005 | $10.43 M(+88.9%) | $10.43 M(+88.9%) |
| Dec 2004 | $5.52 M | $5.52 M |
FAQ
- What is Emergent BioSolutions annual accounts payable?
- What is the all time high annual accounts payable for Emergent BioSolutions?
- What is Emergent BioSolutions annual accounts payable year-on-year change?
- What is Emergent BioSolutions quarterly accounts payable?
- What is the all time high quarterly accounts payable for Emergent BioSolutions?
- What is Emergent BioSolutions quarterly accounts payable year-on-year change?
What is Emergent BioSolutions annual accounts payable?
The current annual accounts payable of EBS is $112.20 M
What is the all time high annual accounts payable for Emergent BioSolutions?
Emergent BioSolutions all-time high annual accounts payable is $136.10 M
What is Emergent BioSolutions annual accounts payable year-on-year change?
Over the past year, EBS annual accounts payable has changed by +$8.70 M (+8.41%)
What is Emergent BioSolutions quarterly accounts payable?
The current quarterly accounts payable of EBS is $82.10 M
What is the all time high quarterly accounts payable for Emergent BioSolutions?
Emergent BioSolutions all-time high quarterly accounts payable is $151.80 M
What is Emergent BioSolutions quarterly accounts payable year-on-year change?
Over the past year, EBS quarterly accounts payable has changed by -$30.60 M (-27.15%)